As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Results presented here showed patients who had significant weight loss prior to total hip arthroplasty with use of a GLP-1 receptor agonist experienced a decreased risk for complications but an ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Getting a headache and feeling sick are common side-effects for many medicines. Indulging in risky sexual behaviour or pathological gambling – not so common. But a BBC investigation has highlighted ...

Despite substantial health benefits, two GLP-1 receptor agonists weren't cost-effective at their current prices, according to ...

The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe form of liver disease. Learn more.

Xi’an Xintong Medicine Research Co. Ltd. has disclosed thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, ...